{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:36:27Z","timestamp":1762907787389,"version":"3.45.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-025-05018-1","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:32:58Z","timestamp":1762907578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the relation of CD133 expression measured by immunohistochemistry assay with the survival of the colorectal cancer patients: a retrospective cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5177-5530","authenticated-orcid":false,"given":"Maliheh","family":"Naghavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5959-6693","authenticated-orcid":false,"given":"Keyvan","family":"Nikkhah Bahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5239-7967","authenticated-orcid":false,"given":"Ali","family":"Ezzatollahi Tanha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-1860","authenticated-orcid":false,"given":"Farzane","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8814-4487","authenticated-orcid":false,"given":"Niloofar","family":"Nikkhahbahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-0852","authenticated-orcid":false,"given":"Ahmad","family":"Jalilvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"3","key":"5018_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"5018_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104740","volume":"26","author":"K Sawai","year":"2025","unstructured":"Sawai K, Koneri K, Kimura Y, Goi T (2025) CD133 expression in circulating tumor cells as a prognostic marker in colorectal cancer. Int J Mol Sci 26(10):4740","journal-title":"Int J Mol Sci"},{"key":"5018_CR3","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen Y-J, Ciombor KK et al (2024) Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Canc Netw 22(2D):e240029"},{"issue":"1","key":"5018_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 34(1):10\u201332","journal-title":"Ann Oncol"},{"key":"5018_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1532924","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zhu H, Liu W, Miao J, Mao Y, Li Q (2025) Prognostic and predictive molecular biomarkers in colorectal cancer. Front Oncol 15:1532924","journal-title":"Front Oncol"},{"issue":"3","key":"5018_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41(3):678\u2013700","journal-title":"J Clin Oncol"},{"issue":"8","key":"5018_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084140","volume":"25","author":"P Radu","year":"2024","unstructured":"Radu P, Zurzu M, Tigora A, Paic V, Bratucu M, Garofil D et al (2024) The impact of cancer stem cells in colorectal cancer. Int J Mol Sci 25(8):4140","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5018_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","volume":"7","author":"PM Glumac","year":"2018","unstructured":"Glumac PM, LeBeau AM (2018) The role of CD133 in cancer: a concise review. Clin Transl Med 7(1):18","journal-title":"Clin Transl Med"},{"issue":"6","key":"5018_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061300","volume":"13","author":"DL Pricope","year":"2025","unstructured":"Pricope DL, Grigora\u0219 A, Dimofte GM, Terinte C, Amalinei C (2025) CD133 and CD166 stem cells markers expression, clinicopathological parameters, and fragmentation response patterns of ypT3 rectal cancer following neoadjuvant chemoradiotherapy. Biomedicines 13(6):1300","journal-title":"Biomedicines"},{"issue":"5","key":"5018_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/jir.2021.0207","volume":"42","author":"S Guan","year":"2022","unstructured":"Guan S, Yang R, Wu S, Xu K, Yang C (2022) The CD133(+)CXCR4(+) colorectal tumor cells promote colorectal cancer progression by PI3K\/AKT signaling. J Interferon Cytokine Res 42(5):195\u2013202","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"5018_CR11","first-page":"19","volume":"21","author":"M Okada","year":"2021","unstructured":"Okada M, Kawai K, Sonoda H, Shiratori H, Kishikawa J, Nagata H et al (2021) Epithelial-mesenchymal transition and metastatic ability of CD133(+) colorectal cancer stem-like cells under hypoxia. Oncol Lett 21(1):19","journal-title":"Oncol Lett"},{"issue":"32","key":"5018_CR12","doi-asserted-by":"publisher","first-page":"e16709","DOI":"10.1097\/MD.0000000000016709","volume":"98","author":"YY Park","year":"2019","unstructured":"Park YY, An CH, Oh ST, Chang ED, Lee J (2019) Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. Medicine (Baltimore) 98(32):e16709","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"5018_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5604\/01.3001.0014.0999","volume":"92","author":"O Kostovski","year":"2020","unstructured":"Kostovski O, Antovic S, Trajkovski G, Kostovska I, Jovanovic R, Jankulovski N (2020) High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer. Pol Przegl Chir 92(3):9\u201314","journal-title":"Pol Przegl Chir"},{"issue":"23","key":"5018_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010446","volume":"97","author":"R Huang","year":"2018","unstructured":"Huang R, Mo D, Wu J, Ai H, Lu Y (2018) CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: an updated meta-analysis of 37 studies. Medicine (Baltimore) 97(23):e10446","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"5018_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/sj.bjc.6604664","volume":"99","author":"D Horst","year":"2008","unstructured":"Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99(8):1285\u20131289","journal-title":"Br J Cancer"},{"key":"5018_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-56","volume":"7","author":"CY Li","year":"2009","unstructured":"Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ et al (2009) Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 7:56","journal-title":"J Transl Med"},{"issue":"3","key":"5018_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/modpathol.2009.181","volume":"23","author":"CW Ong","year":"2010","unstructured":"Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R et al (2010) CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 23(3):450\u2013457","journal-title":"Mod Pathol"},{"issue":"8","key":"5018_CR18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1349-7006.2008.00849.x","volume":"99","author":"M Kojima","year":"2008","unstructured":"Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A (2008) Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99(8):1578\u20131583","journal-title":"Cancer Sci"},{"issue":"8","key":"5018_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147(8):573\u2013577","journal-title":"Ann Intern Med"},{"issue":"5","key":"5018_CR20","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360\u2013363","journal-title":"Fam Med"},{"issue":"2","key":"5018_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.7314\/APJCP.2016.17.2.603","volume":"17","author":"A Koochak","year":"2016","unstructured":"Koochak A, Rakhshani N, Karbalaie Niya MH, Tameshkel FS, Sohrabi MR, Babaee MR et al (2016) Mutation analysis of KRAS and BRAF genes in metastatic colorectal cancer: a first large scale study from Iran. Asian Pac J Cancer Prev 17(2):603\u2013608","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"5018_CR22","first-page":"355","volume":"11","author":"A Yari","year":"2020","unstructured":"Yari A, Afzali A, Aalipour M, Nakheai M, Zahedi MJ (2020) KRAS and BRAF mutations in Iranian colorectal cancer patients: a systematic review and meta-analysis. Caspian J Intern Med 11(4):355\u2013369","journal-title":"Caspian J Intern Med"},{"issue":"10","key":"5018_CR23","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.15419\/bmrat.v4i10.374","volume":"4","author":"M Payandeh","year":"2017","unstructured":"Payandeh M, Amirifard N, Sadeghi M, Shazad B, Farshchian N, Sadeghi E et al (2017) The prevalence of KRAS mutation in colorectal cancer patients in Iran population: a systematic review and meta-analysis study. Biomed Res Ther 4(10):1693\u20131704","journal-title":"Biomed Res Ther"},{"issue":"10","key":"5018_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/oncolo\/oyae152","volume":"29","author":"J Gonz\u00e1lez-Montero","year":"2024","unstructured":"Gonz\u00e1lez-Montero J, Rojas CI, Burotto M (2024) Predictors of response to immunotherapy in colorectal cancer. Oncologist 29(10):824\u2013832","journal-title":"Oncologist"},{"issue":"2","key":"5018_CR25","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.1371\/journal.pone.0056380","volume":"8","author":"S Chen","year":"2013","unstructured":"Chen S, Song X, Chen Z, Li X, Li M, Liu H et al (2013) CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS ONE 8(2):e56380","journal-title":"PLoS ONE"},{"issue":"24","key":"5018_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417398","volume":"24","author":"A Gisina","year":"2023","unstructured":"Gisina A, Kim Y, Yarygin K, Lupatov A (2023) Can CD133 be regarded as a prognostic biomarker in oncology: pros and cons. Int J Mol Sci 24(24):17398","journal-title":"Int J Mol Sci"},{"key":"5018_CR27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7054","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Peng J, Zhang E, Jiang N, Li J, Zhang Q et al (2016) CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.7054","journal-title":"Oncotarget"},{"issue":"18","key":"5018_CR28","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3748\/wjg.15.2258","volume":"15","author":"D Choi","year":"2009","unstructured":"Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH et al (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15(18):2258\u20132264","journal-title":"World J Gastroenterol"},{"issue":"17","key":"5018_CR29","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3748\/wjg.v19.i17.2603","volume":"19","author":"F Ren","year":"2013","unstructured":"Ren F, Sheng WQ, Du X (2013) CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 19(17):2603\u20132611","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5018_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/labinvest.2011.185","volume":"92","author":"C Chao","year":"2012","unstructured":"Chao C, Carmical JR, Ives KL, Wood TG, Aronson JF, Gomez GA et al (2012) CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133\u2212 cells. Lab Invest 92(3):420\u2013436","journal-title":"Lab Invest"},{"issue":"1","key":"5018_CR31","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"key":"5018_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111364","volume":"137","author":"Z Asadzadeh","year":"2021","unstructured":"Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D et al (2021) The combination effect of Prominin1 (CD133) suppression and oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother 137:111364","journal-title":"Biomed Pharmacother"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-05018-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:33:00Z","timestamp":1762907580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-05018-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5018"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-05018-1","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Ethics Committee of Zanjan University of Medical Sciences (Approval Code: IR.ZUMS.REC.1402.164). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}